Tag Archive for Growth Hormone Releasing Peptide

GHRP-6 Hexapeptide Dosage

 GHRP-6 Hexapeptide Dosage

Light: 50mcg
Common: 100mcg
Large: 150mcg

Growth Hormone Releasing Peptide (GHRP-6) is a peptide in the growth factor family. It has strong effect on the release of Human Growth Hormone (HGH) in a specific and dose-related manner. GHRP can be effectively used in the treatment of growth hormone (GH) deficiency. Growth hormone releasing hexapeptide works by signaling the pituitary gland to begin growth hormone secretion.

Increased GH and IGF-1 levels are desirable for those looking to improve physique. Human growth hormone has been known to enhance immune response and stimulate the immune system, particularly older subjects. Dosed at night for anti-aging purposes and multiple times throughout the day for anabolism. GHRP is often used in conjunction with GHRH CJC-1295 (mod GRF 1-29) to amplify growth hormone pulse. Avoid fats and carbohydrate a half hour on each side of dosing GHRP-6.

Bodybuilders and athletes dose GHRP in an effort to build more muscle and burn fat. Some GHRP-6 users include it in their post cycle therapy (PCT). Cycling GHRP-6 in the off weeks from IGF/GH cycles is also becoming prevalent. Researchers wish to kick-start their body into producing their own natural GH & IGF, while gaining as if they remained on the GH/IGF peptides.

GHRP-6′s main use is to promote food intake by stimulating hunger and aid in energy metabolism. The major side effect being a significant increase in appetite due to a stimulating the release of Ghrelin (about 20 minutes post injection), a hormone released naturally in the lining of the stomach and increases hunger and gastric emptying. This is why GHRP-6 can be used in the treatment of cachexia (wasting), eating disorders and obesity.

Benefits of increased HGH levels through GHRP-6 stimulation include: an increase in strength, muscle mass and body fat loss, rejuvenation and strengthening of joints, connective tissue and bone mass. Enhanced HGH secretion also leads to the liver secreting more IGF-1, which is thought to be the primary anabolic mechanism of action for Growth Hormone.

Bodybuilding Peptide GHRP-6 reconstitution


Mixing: Bacteriostatic water is used for reconstitution. When diluted, peptide lasts a very long time when left alone in the refrigerator (months)

Example- 2.5ml(cc) bacteriostatic water per 5mg GHRP vial equates to a 100mcg dose approximately each 2-3 marks on a U100 insulin syringe.
Example- 5ml(cc) bacteriostatic water per 5mg GHRP vial equates to a 100mcg dose approximately every 5 marks on a U100 insulin syringe.

Dosing: The saturation dose of GHRP-6 has been determined to be around 100mcg. More is not better in regards to this secretagogue

5mg GHRP = 5,000mcg
5,000mcg/100mcg = 50 100mcg GHRP doses per 5mg

Share with your friendsEmail this to someoneTweet about this on TwitterShare on Google+Share on FacebookPin on PinterestDigg thisShare on StumbleUponShare on TumblrShare on Reddit



Ipamorelin is a growth hormone releasing peptide. It stimulates the body to release more human growth hormone and igf-1. Increases in gh and igf-1 can result in many benefits including:

- Builds Lean Tissue
- Lowers Body Fat
- Improved Recovery from training
- anti aging
- Improves Mood and Sleep Patterns

Ipamorelin is similar to other GHRP’s such as GHRP-2 and GHRP-6. However Ipamorelin does not cause sudden spikes in prolactin or cortisol like GHRP-2 and GHRP-6 can do. Both of those hormones when elevated can cause negative side effects. Cortisol is a steroid hormone that is released when stressed and can be very catabolic. Prolactin counteracts the effect of dopamine, which is responsible for sexual arousal. Elevated prolactin can cause a variety of unwanted physical and psychological effects.

Raun K et al. (1998) highlighted ipamorelin’s beneficial effects over the other ghrp’s. In pentobarbital anaesthetised rats, ipamorelin released GH with a potency and efficacy comparable to GHRP-6. In conscious swine, gh release after ipamorelin injection was high and again vey similar to GHRP6. In the same study GHRP-2 displayed higher potency but lower efficacy. The specificity for GH release was studied in swine. They found none of the GH secretagogues tested affected FSH, LH, PRL or TSH plasma levels. Administration of both GHRP-6 and GHRP-2 resulted in increased plasma levels of ACTH and cortisol. Very surprisingly, ipamorelin did not release ACTH or cortisol in levels significantly different from those observed following GHRH stimulation. This lack of effect on ACTH and cortisol plasma levels was evident even when extremely high doses of were used. Ipamorelin was the first GHRP-receptor agonist with a selectivity for GH release similar to that displayed by GHRH.

A pharmacological profiling using GHRP and growth hormone-releasing hormone (GHRH) antagonists clearly demonstrated that ipamorelin, like GHRP-6, stimulates GH release via a GHRP-like receptor. However ipameolin is slow in its delivery unlike GHRP’s which spike GH levels at a faster rate. This another notable difference when researching ghrp’s. Moreover it has been shown that Ipamorelin is able to exert a dynamic control effect on the somatotroph population and on GH hormone content (Jiménez-Reina L et al. 2002).

A variety of promising effects have been displayed when ipamorelin has been studied. Adeghate E et al. (2004) examined the effect ipamorelin had on insulin secretion from pancreatic tissue fragments of normal and diabetic rats. Ipamorelin evoked significant (p<0.04) increases in insulin secretion from the pancreas of normal and diabetic rats. It was shown that ipamorelin stimulates insulin release through the calcium channel and the adrenergic receptor pathways.

Nitrogen balance is very important in humans. A positive value is often found during periods of growth, tissue repair or pregnancy. This means that the intake of nitrogen into the body is greater than the loss of nitrogen from the body, so there is an increase in the total body pool of protein. A negative value can be associated with burns, fevers, wasting diseases and other serious injuries and during periods of fasting. This means that the amount of nitrogen excreted from the body is greater than the amount of nitrogen ingested. Aagaard NK et al. (2009) studied the metabolic effects of Ipamorelin on selected hepatic measures of alpha-amino-nitrogen conversion during steroid-induced catabolism. Prednisolone was the steroid used to induce this catabolism. In prednisolone treated rats ipamorelin reduced CUNS by 20% (p<0.05), decreased the expression of urea cycle enzymes, neutralised N-balance, and normalized or improved organ N-contents. Therefore accelerated nitrogen wasting in the liver and other organs caused by prednisolone treatment was counteracted by treatment with Ipamorelin.

Ipamorelin is ideal for pre bed dosing

due to it’s long active life and minimal effect on hunger levels. When other GHRP’s are used such as GHRP 2/6 they can cause a sudden increase in appetite which can be awkward pre bed. Doses as little as 200mcg are highly effective but I feel Ipamorelin truly shines when you boom dose it. I have gone up to as much as 1mg pre bed and that was incredible. Although for most a dose of 500mcg would be more than enough when combined with a GHRH. My favourite peptide cycle to date has been CJC-1295 DAC with GHRP-2 through the day. Then a high dose of Ipam used pre bed.

Finally just want to list what I feel is a key advantage ipamorelin has over GH injections in a research environment. Unlike GH injections it does not shut down the body’s natural production of this hormone, it just enhances it. In the long run this is a huge factor and I feel future studies will highlight the importance of this in relation to health.


1. Aagaard NK, Gr&amp;oslash;fte T, Greisen J, Malml&amp;ouml;f K, Johansen PB, Gr&amp;oslash;nbaek H, &amp;Oslash;rskov H, Tygstrup N, Vilstrup H (2009) Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats. PMID: 19231263 [PubMed - indexed for MEDLINE]
2. Adeghate E, Ponery AS (2004) Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. PMID: 15665799 [PubMed - indexed for MEDLINE]
3. Raun K, Hansen BS, Johansen NL, Th&amp;oslash;gersen H, Madsen K, Ankersen M, Andersen PH (1998) Ipamorelin, the first selective growth hormone secretagogue. PMID: 9849822 [PubMed - indexed for MEDLINE]
4. Jim&amp;eacute;nez-Reina L, Ca&amp;ntilde;ete R, de la Torre MJ, Bernal G (2002) Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro. PMID: 12168778 [PubMed - indexed for MEDLINE]

Share with your friendsEmail this to someoneTweet about this on TwitterShare on Google+Share on FacebookPin on PinterestDigg thisShare on StumbleUponShare on TumblrShare on Reddit
eXTReMe Tracker